IL-6 amplifies TLR mediated cytokine and chemokine production: Implications for the pathogenesis of rheumatic inflammatory diseases

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Caiello, Ivan ^a   Minnone, Gaetana ^a   Holzinger, Dirk ^b   Vogl, Thomas ^b   Prencipe, Giusi ^a   Manzo, Antonio ^c   De Benedetti, Fabrizio ^a   Strippoli, Raffaele ^a,d  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CHEMOKINE; CYTOKINE; LIGAND;

ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; MOLECULAR PATHOLOGY; MONONUCLEAR CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG EFFECTS; FIBROBLAST; METABOLISM; RHEUMATIC DISEASE; SYNOVIUM;

CHEMOKINES; CYTOKINES; FIBROBLASTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIGANDS; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTORS;

EID: 84907546570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107886     Document Type: Article

References (36)

1. Nishimoto N, Kishimoto T. (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619-626.
2. Heinrich PC, Behrmann I, Haan S., Hermanns HM, Muller-Newen G, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20.
3. Naugler WE, Karin M. (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14: 109-119.
4. De Benedetti F, Brunner HI, Ruperto N, Kenwright A., Wright S, et al. (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367: 2385-2395.
5. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997.
6. Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51 Suppl 5: v3-11.
7. Ogura H, Murakami M, Okuyama Y., Tsuruoka M, Kitabayashi C, et al. (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29: 628-636.
8. Samson M, Audia S, Janikashvili N., Ciudad M, Trad M, et al. (2012) Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 64: 2499-2503.
9. Takeuchi O, Akira S. (2010) Pattern recognition receptors and inflammation. Cell 140: 805-820.
10. Erridge C (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
11. Gerss J, Roth J, Holzinger D., Ruperto N, Wittkowski H, et al. (2012) Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 71: 1991-1997.
12. Holzinger D, Frosch M, Kastrup A., Prince FH, Otten MH, et al. (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71: 974-980.
13. Sokolove J, Zhao X, Chandra P.E., Robinson W.H. (2011) Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 63: 53-62.
14. Strippoli R, Carvello F, Scianaro R., De Pasquale L, Vivarelli M, et al. (2012) Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 64: 1680-1688.
15. Scire CA, Epis O, Codullo V., Humby F, Morbini P, et al. (2007) Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Res Ther 9: R101.
16. De Benedetti F, Pignatti P, Gerloni V., Massa M, Sartirana P, et al. (1997) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 24: 1403-1409.
17. Schindler R, Mancilla J, Endres S., Ghorbani R, Clark SC, et al. (1990) Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75: 40-47.
18. Brown KD, Claudio E, Siebenlist U. (2008) The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoim-munity and rheumatoid arthritis. Arthritis Res Ther 10: 212.
19. Buss H, Dorrie A, Schmitz M.L., Hoffmann E., Resch K, et al. (2004) Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 279: 55633-55643.
20. Strippoli R, Benedicto I, Foronda M., Perez-Lozano ML, Sanchez-Perales S, et al. (2010) p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J Cell Sci 123: 4321-4331.
21. Prencipe G, Minnone G, Strippoli R., De Pasquale L, Petrini S, et al. (2014) Nerve Growth Factor Downregulates Inflammatory Response in Human Monocytes through TrkA. J Immunol 192: 3345-3354.
22. Nishimoto N, Ito A, Ono M., Tagoh H, Matsumoto T, et al. (2000) IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. Int Immunol 12: 187-193.
23. Xing Z, Gauldie J, Cox G., Baumann H, Jordana M, et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320.
24. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813: 878-888.
25. Alonzi T, Fattori E, Lazzaro D., Costa P, Probert L, et al. (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187: 461-468.
26. Fattori E, Cappelletti M, Costa P., Sellitto C, Cantoni L, et al. (1994) Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180: 1243-1250.
27. Aderka D, Le JM, Vilcek J. (1989) IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143: 3517-3523.
28. Ruperto N, Brunner HI, Quartier P, Constantin T., Wulffraat N, et al. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367: 2396-2406.
29. Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40: 599-606.
30. Stein N, Witt M, Baeuerle M., Proft F, Schulze-Koops H, et al. (2012) Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome. ACR abstract 747.
31. Wang L, Walia B, Evans J., Gewirtz AT, Merlin D, et al. (2003) IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol 171: 3194-3201.
32. Yoshida Y, Kumar A, Koyama Y., Peng H, Arman A, et al. (2004) Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem 279: 1768-1776.
33. Asensi V, Valle E, Meana A., Fierer J, Celada A, et al. (2004) In vivo interleukin-6 protects neutrophils from apoptosis in osteomyelitis. Infect Immun 72: 3823-3828.
34. Chomarat P, Banchereau J, Davoust J., Palucka A.K. (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1: 510-514.
35. Zlotnik A, Yoshie O. (2012) The chemokine superfamily revisited. Immunity 36: 705-716.
36. Brentano F, Schorr O, Gay R.E., Gay S., Kyburz D. (2005) RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 52: 2656-2665.